Conference Coverage

Chemotherapy-induced peripheral neuropathy tied to compromised executive function


 

AT AANEM 2023

Need for increased awareness

Commenting on the study, Ting Bao, MD, co-director of the Leonard P. Zakim Center for Integrative Therapies & Healthy Living at the Dana-Farber Cancer Institute, Boston, said that the findings underscore that “there is a need for increased awareness of the diverse manifestations of chemotherapy-induced neuropathy.”

These include the fact that “neurotoxic chemotherapy impacts both the peripheral and central nervous systems, affecting balance through distinct mechanisms.”

Although treatments routinely recommended for CIPN include duloxetine, tricyclic antidepressants, or gabapentin as well as topical agents such as lidocaine, evidence also shows benefits of nonpharmacologic approaches including exercise, acupuncture, and yoga. Dr. Bao’s own research has suggested that those benefits can extend improved balance and reduced fall risk.

Dr. Bao and colleagues recently conducted a randomized study that included 41 patients with CIPN to receive either yoga or usual care.

“The findings revealed that after eight biweekly sessions of yoga, there was a notable improvement in the far-reach test, which is a predictor of fall risk,” she said.

To validate these findings, the researchers are currently conducting a larger randomized controlled trial, she said.

In the meantime, “further research into the mechanisms and effective treatments for chemotherapy-induced neurotoxicity is essential,” added Dr. Bao.

Dr. McNeish and Dr. Bao report no relevant disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

The dawning age of therapy for Friedreich ataxia
MDedge Neurology
Stiff person syndrome: When a rare disorder hits the headlines
MDedge Neurology
FDA okays drug for Duchenne muscular dystrophy
MDedge Neurology
In myasthenia gravis, antibodies pass open-label tests
MDedge Neurology
Genetic therapies bring change to neurology clinics
MDedge Neurology
Duchenne muscular dystrophy gene therapy safe, effective at 4 years
MDedge Neurology
First new treatment in 30 years for rare disease is effective, tolerable, convenient
MDedge Neurology
‘Hidden’ cognitive impairments in DMD may worsen outcomes
MDedge Neurology
U.S. study finds unexpectedly high prevalence of myasthenia gravis
MDedge Neurology
Artificial intelligence presents opportunities, challenges in neurologic practice
MDedge Neurology